Medtronic Updates Earnings and Revenue Outlook

Medtronic (NYSE:MDT) has narrowed its annual earnings forecast for fiscal 2025 but raised its organic revenue growth outlook. The company’s shares rose nearly 1% in premarket trading on Tuesday.

Fiscal Q2 Performance

For fiscal Q2, the medical device maker reported adjusted earnings per share (EPS) of $1.26, which slightly exceeded the consensus estimate of $1.25. Revenue for the period was $8.4 billion, surpassing analyst expectations of $8.28 billion.

Updated Guidance for Fiscal 2025

Looking ahead, Medtronic updated its full-year fiscal 2025 guidance, narrowing its adjusted EPS outlook to a range of $5.44 to $5.50, compared to the previous range of $5.42 to $5.50, aligning closely with the consensus estimate of $5.45.

The company also revised its organic revenue growth forecast, now expecting a range of 4.75% to 5%, up from the earlier estimate of 4.5% to 5%.

CEO’s Statement

"Our momentum is building as we keep executing on our commitments, delivering yet another consecutive quarter of strong results that came in ahead of expectations," said Geoff Martha, chairman and CEO of Medtronic.

"Innovation matters, and innovation is driving our growth today. We are confident that this diversified growth will continue, especially given the strength of our pipeline in high-impact markets that will benefit more patients around the world."